A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A new mRNA vaccine against the flu has proven itself more effective than existing vaccines in a new clinical trial. The ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Vaccine experts said the memo was irresponsible and omits key details about how officials arrived at the conclusion.

We use the TipRanks Stock Comparison tool to see how Wall Street analysts are rating Novavax, BioNTech, and Moderna, and ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

The chair of a federal vaccine advisory committee, himself a well-known vaccine critic, will be moving to an official role ...